Yesterday Minister Røe Isaksen and the Minister of Health Bent Høie visited Lytix Biopharma at the Department of Cell therapy at the Cancer Research Institute/Oslo University Hospital. The background is that the Government will present a long-term plan for research and higher education on October 8. This white paper will outline how the government will prioritize the use of research resources in the coming years.
Health, nutrition and outstanding research are some of the priority areas, and the long-term plan will also follow up on Health&Care21. Both Ministers pointed out that Lytix Biopharma is a good example of several aspects of the plan.
CEO Unni Hjelmaas in Lytix Biopharma appreciate the contact with both ministries.
Right focus from the Government
– It is an honor for Lytix Biopharma to be part of this and at the same time be acknowledged for many of the objectives set in the long term plan for research and higher education as well as the Health&Care21, says Hjelmaas. We are ensured that the Government has the right focus after the insight we got into the long term plan today. We now look forward to seeing this be moved from words to action.
The General Manager of the Pharma Industry Association in Norway Karita Bekkemellem was also present. She was very enthusiastic after the meeting. – This is a recognition that the pharma industry is an important contributor to good patient treatment. It is positive that the Government now focus on an active public and academic partnership with the pharma industry. We look forward to contribute, she continues.
Long-term research and higher education
The Government announced in May that it will present a long-term plan for research and higher education in autumn 2014. The objective is a strategic, coordinated and predictable research and higher education policy that lays the foundation for Norway to meet the challenges and opportunities ahead of us.
The long-term plan is a tool to target efforts on areas where Norway has strategic advantages, and to meet future needs for knowledge in key areas. At the same time the long-term plan allow for crossing borders and for innovative research that can give us new insight in the long term.
Lytix Biopharma’s technology is based on nature’s own defense mechanism. The membranes of bacteria and cancer cells are destroyed. Our technology has the potential to meet two substantial medical challenges; treatment of infections regardless of resistance and cancer therapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners for the final stages of product development and commercialization. See www.lytixbiopharma.com.